Bardin Hill Management Partners LP Invests $10.32 Million in Catalent, Inc. (NYSE:CTLT)

Bardin Hill Management Partners LP bought a new stake in shares of Catalent, Inc. (NYSE:CTLT) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 170,380 shares of the company’s stock, valued at approximately $10,320,000. Catalent makes up 4.8% of Bardin Hill Management Partners LP’s investment portfolio, making the stock its 6th largest holding. Bardin Hill Management Partners LP owned about 0.09% of Catalent at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Swedbank AB purchased a new stake in Catalent in the 1st quarter worth approximately $1,659,000. DekaBank Deutsche Girozentrale increased its stake in shares of Catalent by 2.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 31,445 shares of the company’s stock worth $1,763,000 after purchasing an additional 732 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares in the last quarter. DNB Asset Management AS raised its position in shares of Catalent by 10.4% during the 2nd quarter. DNB Asset Management AS now owns 30,598 shares of the company’s stock valued at $1,721,000 after purchasing an additional 2,887 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent in the 2nd quarter worth $42,000.

Insider Transactions at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock worth $305,931 in the last three months. Insiders own 0.31% of the company’s stock.

Catalent Price Performance

Shares of Catalent stock opened at $61.11 on Monday. The firm has a market cap of $11.09 billion, a PE ratio of -27.04, a PEG ratio of 2.43 and a beta of 1.16. The stock has a 50 day moving average of $59.90 and a 200 day moving average of $58.51. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the business posted ($0.10) earnings per share. On average, research analysts expect that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on CTLT. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. William Blair reissued a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.